Cosmos Holdings (COSM) AI Stock Analysis

• Market Cap: $17.52M
• Dividend Yield: N/A
• Average Volume (3M): 1.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.06
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.53
• Shares Outstanding: 37,432,520
• 10 Day Avg. Volume: 1,246,475
• 30 Day Avg. Volume: 1,183,471
• PEG Ratio: 0.02
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 0.24
• P/FCF Ratio: -1.57
• Enterprise Value/Market Cap: 1.84
• Enterprise Value/Revenue: 0.54
• Enterprise Value/Gross Profit: 4.71
• Enterprise Value/Ebitda: -2.16
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.48 ▼(-7.69% Downside)

The score is driven primarily by weak financial performance (losses and negative cash flow) and bearish technicals (below key moving averages with negative MACD). Valuation is constrained by unprofitability (negative P/E), and the Nasdaq non-compliance notice adds additional downside risk.

Positive Factors

Robust supply chain & distribution network

A global, well-established distribution network and supply chain provide durable competitive advantage by enabling broad market coverage, lower logistics disruption risk, and scalable wholesale/retail distribution. This supports steady revenue access across channels over months.

Partnerships with international manufacturers

Strategic partnerships expand product assortment and market access without proportionate fixed-cost increases. Long-term, such alliances enhance product pipeline breadth, marketing reach, and margin leverage by enabling access to new markets and branded/generic supply sources.

Modest recurring revenue growth (TTM +8.53%)

Sustained revenue growth indicates demand traction for its distribution and retail channels. Over a 2-6 month horizon, consistent top-line expansion supports capacity utilization, bargaining power with suppliers, and the potential to progressively improve gross margins if cost control persists.

Negative Factors

Persistent unprofitability & weak margins

Negative net and EBIT margins show the company is not yet converting sales into sustainable profits. Over time this pressures retained earnings, limits reinvestment capacity, and forces reliance on external financing or corrective restructuring to achieve durable profitability.

Negative operating cash flow and cash-generation issues

Operating cash flow that is negative indicates core business cannot self-fund operations and growth. This structural cash-generation shortfall elevates refinancing risk, constrains capex and R&D, and may compel asset sales or dilutive funding over the medium term.

Nasdaq non-compliance notice & potential reverse split

A Nasdaq minimum bid-price notice risks listing status and may force a reverse split, which can dilute shareholders, reduce liquidity, and signal weakness to counterparties. This is a structural governance and capital-structure risk affecting investor access and long-term credibility.

Cosmos Holdings Business Overview & Revenue Model

Company Description

Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.

How the Company Makes Money

Cosmos Holdings generates revenue through multiple streams, including the wholesale distribution of pharmaceuticals, which involves sourcing products from manufacturers and selling them to pharmacies, hospitals, and clinics. The company also profits from its retail operations, which include direct sales of over-the-counter medications and dietary supplements to consumers. Additionally, Cosmos Holdings engages in partnerships with international manufacturers, allowing it to expand its product offerings and leverage marketing opportunities. These partnerships enhance its revenue potential by providing access to a broader range of products and markets, thus contributing to its overall earnings.

Cosmos Holdings Financial Statement Overview

Summary

Weak fundamentals overall: modest revenue growth, but persistent losses and negative margins, negative operating/free cash flow, and negative ROE. Leverage appears manageable, but equity strength and cash generation are key risks.

Income Statement

Cosmos Holdings has shown some improvement in revenue growth with an 8.53% increase in the TTM period. However, profitability remains a concern with negative net profit margins and EBIT margins, indicating ongoing operational challenges. The gross profit margin has slightly improved but remains low, reflecting pressure on cost management.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.58, suggesting manageable leverage. However, the return on equity is negative, indicating that the company is not generating sufficient returns on shareholders' equity. The equity ratio is also low, highlighting potential risks in financial stability.

Cash Flow

Cosmos Holdings' cash flow situation is concerning, with negative operating cash flow and free cash flow. Although there is a positive free cash flow growth rate, the operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is positive, suggesting some efficiency in converting earnings to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	59.79M	54.43M	53.38M	50.35M	56.24M	55.41M
Gross Profit	6.82M	4.31M	4.35M	5.96M	8.33M	8.06M
EBITDA	-14.92M	-13.92M	-17.06M	-8.90M	-3.82M	4.39M
Net Income	-18.54M	-16.18M	-18.54M	-13.83M	-7.96M	820.79K
Balance Sheet
Total Assets	69.49M	54.31M	66.01M	68.04M	49.43M	43.84M
Cash, Cash Equivalents and Short-Term Investments	922.62K	336.25K	3.85M	20.76M	297.95K	851.19K
Total Debt	21.07M	11.82M	12.42M	12.03M	27.12M	32.04M
Total Liabilities	46.36M	29.78M	29.97M	28.38M	45.05M	48.01M
Stockholders Equity	23.13M	24.53M	36.04M	39.66M	4.38M	-4.16M
Cash Flow
Free Cash Flow	-10.27M	-8.14M	-24.80M	-15.25M	-7.99M	-11.62M
Operating Cash Flow	-9.20M	-7.72M	-15.64M	-14.87M	-7.10M	-11.50M
Investing Cash Flow	-1.95M	-798.27K	-13.76M	-21.50K	-826.82K	-117.74K
Financing Cash Flow	12.49M	5.05M	12.69M	35.05M	7.27M	12.46M

Cosmos Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Negative. The current price of 0.52 is above the 20-day moving average (MA) of 0.50, above the 50-day MA of 0.51, and below the 200-day MA of 0.65, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.11 is Neutral, neither overbought nor oversold. The STOCH value of 25.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COSM.

Cosmos Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TXMD	52 Neutral	$26.04M	83.91	0.27%	―	75.19%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCYX	45 Neutral	$30.42M	-1.29	-53.29%	―	-65.77%	38.61%
AYTU	45 Neutral	$25.22M	-0.60	-50.23%	―	-15.61%	-68.96%
PRPH	42 Neutral	$1.28M	>-0.01	―	―	―	―
RMTI	42 Neutral	$40.59M	-6.27	-16.67%	―	-23.60%	-179.33%
COSM	40 Underperform	$17.52M	-0.62	-63.82%	―	―	―

Cosmos Holdings Corporate Events

Cosmos Health Receives Nasdaq Non-Compliance Bid Price Notice

On December 11, 2025, Cosmos Health Inc. disclosed that it had received a notice from Nasdaq indicating non-compliance with the exchange’s minimum bid price requirement, as the company’s shares had traded below $1.00 for 30 consecutive business days. The company has 180 calendar days from that date to restore compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive sessions, and has indicated it intends to pursue a reverse stock split if needed, a step that could affect shareholder dilution and signal efforts to preserve its Nasdaq listing and market visibility.

The most recent analyst rating on (COSM) stock is a Sell with a $0.43 price target. To see the full list of analyst forecasts on Cosmos Holdings stock, see the COSM Stock Forecast page.